https://pharmadog.xyz/news/134233 pharmadog en 2026-08-10T14:49:00.000Z CLINUVEL to cut up to 20% of staff and move headquarters to New York https://pharmadog.xyz/news/223474 pharmadog en 2026-08-10T14:37:15.000Z Psychedelic firms Definium and Compass poised for key data releases https://pharmadog.xyz/news/223475 pharmadog en 2026-08-10T14:36:19.000Z AstraZeneca and CSPC launch joint venture to build biologics plant in Shijiazhuang https://pharmadog.xyz/news/223291 pharmadog en 2026-08-10T13:45:18.000Z Jazz bets on epilepsy again by acquiring Actio for $820M upfront https://pharmadog.xyz/news/223355 pharmadog en 2026-08-10T13:24:23.000Z STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more https://pharmadog.xyz/news/223079 pharmadog en 2026-08-10T12:57:39.000Z Tenax Therapeutics' heart failure drug TNX-103 misses primary endpoint in Phase 3, shares plunge 85% https://pharmadog.xyz/news/222931 pharmadog en 2026-08-10T12:03:17.000Z Sionna's CF add-on pill fails to improve outcomes in Phase 2 trial with Trikafta https://pharmadog.xyz/news/123082 pharmadog en 2026-08-10T11:53:00.000Z Latigo and BlossomHill file Nasdaq IPO plans to fund pain and cancer pipelines https://pharmadog.xyz/news/222803 pharmadog en 2026-08-10T11:38:20.000Z Tenax Therapeutics’ heart-failure drug misses primary goal in Phase 3 trial, shares tumble https://pharmadog.xyz/news/222759 pharmadog en 2026-08-10T11:31:25.000Z Silence Therapeutics moves siRNA drug for polycythemia vera to Phase 3 after Phase 2 success https://pharmadog.xyz/news/222804 pharmadog en 2026-08-10T11:31:00.000Z Silence Therapeutics’ divesiran shows 88% response in Phase 2 polycythemia vera trial, challenging Takeda’s upcoming drug https://pharmadog.xyz/news/222784 pharmadog en 2026-08-10T11:20:01.000Z BioMarin drops BMN 401 after Phase 3 trial misses clinical endpoints, ending $270M Inozyme asset https://pharmadog.xyz/news/222651 pharmadog en 2026-08-10T11:00:22.000Z BioNTech veteran secures $25M seed round for virtual cancer surveillance startup https://pharmadog.xyz/news/222547 pharmadog en 2026-08-10T10:42:13.000Z Denali Therapeutics' Avlayah generates $3.6M in Q1, beating forecasts https://pharmadog.xyz/news/223425 pharmadog en 2026-08-10T10:09:00.000Z Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug https://pharmadog.xyz/news/223426 pharmadog en 2026-08-10T09:39:00.000Z Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex https://pharmadog.xyz/news/222203 pharmadog en 2026-08-10T09:00:00.000Z Early regulatory operations planning key to submission-ready dossiers https://pharmadog.xyz/news/222185 pharmadog en 2026-08-10T08:30:00.000Z Safety concerns emerge as radiopharmaceuticals advance in cancer trials https://pharmadog.xyz/news/222186 pharmadog en 2026-08-10T08:30:00.000Z States urged to use low-cost, scalable outreach for Medicaid enrollees facing 2027 eligibility changes https://pharmadog.xyz/news/223360 pharmadog en 2026-08-10T08:30:00.000Z Opinion: We prepared for Ebola — but not this Ebola https://pharmadog.xyz/news/222183 pharmadog en 2026-08-10T08:30:00.000Z China clamps down on investigator-initiated clinical trials, tightening oversight https://pharmadog.xyz/news/222184 pharmadog en 2026-08-10T08:30:00.000Z Global Ebola preparedness fixated on one strain, leaving gaps for other species https://pharmadog.xyz/news/223030 pharmadog en 2026-08-10T08:25:00.000Z AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice https://pharmadog.xyz/news/223266 pharmadog en 2026-08-10T08:18:00.000Z Labcorp nabs FDA green light for BRAF melanoma diagnostic https://pharmadog.xyz/news/223031 pharmadog en 2026-08-10T08:14:00.000Z FDA issues alert in wake of BD recall of faulty needle sets that caused four deaths https://pharmadog.xyz/news/222843 pharmadog en 2026-08-10T07:15:00.000Z Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push https://pharmadog.xyz/news/221739 pharmadog en 2026-08-10T07:12:00.000Z AGC Biologics targets in-vivo gene therapies with stable producer lines and next-gen purification https://pharmadog.xyz/news/222330 pharmadog en 2026-08-10T05:06:00.000Z Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program https://pharmadog.xyz/news/222734 pharmadog en 2026-08-10T04:36:00.000Z Silence brings the noise to Takeda with phase 2 blood cancer win https://pharmadog.xyz/news/222114 pharmadog en 2026-08-10T04:29:00.000Z aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug https://pharmadog.xyz/news/221039 pharmadog en 2026-08-10T04:04:00.000Z Biogen’s ALS drug shows symptom improvement in some patients three years after approval https://pharmadog.xyz/news/221040 pharmadog en 2026-08-10T04:03:00.000Z BMS's Cobenfy faces market hurdles as side effects limit uptake, MapLight eyes opportunity https://pharmadog.xyz/news/221041 pharmadog en 2026-08-10T04:02:00.000Z Eli Lilly's $3.8 B acquisition of AtaiBeckley signals growing confidence in psychedelics for depression https://pharmadog.xyz/news/220191 pharmadog en 2026-08-09T23:16:45.000Z Sanofi reports shortages of Myozyme and Nexviazyme for Pompe disease after FDA manufacturing warning https://pharmadog.xyz/news/223032 pharmadog en 2026-08-09T22:33:00.000Z Novo Nordisk and Amazon sign AI drug discovery pact, launch London innovation hub https://pharmadog.xyz/news/220793 pharmadog en 2026-08-09T04:00:00.000Z Taylor Fresh Foods recalls jalapeño-containing products over possible Salmonella contamination